A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to recruit 90 participants who will be randomly assigned to 1 of 3 dose cohorts (30 cases per dose cohort) with up to 6 cycles of treatment in this study.

Trial Details

NCT ID
NCT07567521
Phase
PHASE1 / PHASE2
Sponsor
C Ray Therapeutics
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Radiopharmaceuticals
Locations (sample)
  • Taiyuan, Shanxi, China|37.86944,112.56028
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Participants must have the ability to understand and sign ICF.
  • Participants must have histological, and/or cytological confirmation of adenocarcinoma of the prostate.
  • Participants must have progressive mCRPC after treatment of ARPI or taxane-based chemotherapy.
  • Participant must have been diagnosed with mCRPC with documented progressive disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →